CC
OKUR

Centiva Capital’s OnKure Therapeutics OKUR Stock Holding History

Centiva Capital’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,400
Closed -$36.2K – 2694
2024
Q2 		$36.2K Buy
+2,400
New +$40.7K ﹤0.01% 1946

Other funds holding OKUR

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Centiva Capital's OKUR Position: Q3 2024 in Review

Centiva Capital sold out of OnKure Therapeutics (OKUR) in Q3 2024, closing a stake of 2,400 shares — an estimated $36.2K sold.

Centiva Capital first reported a position in OKUR in Q2 2024 and held it in 1 quarter. The position peaked at $36.2K in Q2 2024. 51 funds tracked by Wall St. Rank hold OKUR as of Q3 2024.

  • Centiva Capital reported no remaining OnKure Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Centiva Capital sold 2,400 OnKure Therapeutics shares in Q3 2024, an estimated $36.2K.
  • Centiva Capital first reported a position in OnKure Therapeutics in Q2 2024 and held it in 1 quarter.
  • Centiva Capital's OnKure Therapeutics position peaked at $36.2K in Q2 2024.
  • 51 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q3 2024.

Based on Centiva Capital's 13F filing for Q3 2024, filed 14 Nov 2024.